Compare NX & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NX | INBX |
|---|---|---|
| Founded | 1927 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 852.1M | 999.7M |
| IPO Year | 2008 | 2024 |
| Metric | NX | INBX |
|---|---|---|
| Price | $18.57 | $102.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $28.00 | ★ $150.00 |
| AVG Volume (30 Days) | 286.5K | ★ 442.3K |
| Earning Date | 06-04-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,837,641,000.00 | $1,300,000.00 |
| Revenue This Year | $4.26 | N/A |
| Revenue Next Year | $1.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 43.81 | ★ 550.00 |
| 52 Week Low | $11.04 | $12.80 |
| 52 Week High | $22.90 | $155.29 |
| Indicator | NX | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 45.50 |
| Support Level | $18.30 | $99.20 |
| Resistance Level | $20.24 | $153.14 |
| Average True Range (ATR) | 0.74 | 11.61 |
| MACD | 0.06 | -3.13 |
| Stochastic Oscillator | 61.78 | 7.41 |
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.